Skip to main content

Table 2 Tumor growth in vivo (%)

From: Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells

  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Average
CD45+ CD19+ CD45+ CD19+ CD45+ CD19+ CD45+ CD19+ CD45+ CD19+ CD45+ CD19+
PBS 87.8 ± 6.8 87.6 ± 9.9 83.5 ± 7.3 83.9 ± 8.9 79.2 ± 9.2 79.6 ± 6.7 85.1 ± 6.1 85.7 ± 8.3 88.3 ± 8.1 88.5 ± 10.4 84.8 ± 5.6 85.1 ± 5.5
T 82.1 ± 5.9 82.8 ± 6.1 80.1 ± 9.4 80.6 ± 5.4 78.2 ± 7.1 78.9 ± 7.8 81.2 ± 5.9 81.0 ± 7.9 80.9 ± 10.9 81.2 ± 7.8 80.5 ± 2.3 80.9 ± 2.0
T + diabody 60.0 ± 7.2 59.8 ± 5.7 60.1 ± 1.6 59.5 ± 5.6 58.8 ± 6.1 58.5 ± 6.5 62.5 ± 2.6 61.9 ± 6.4 62.6 ± 5.7 63.0 ± 3.4 60.8 ± 2.0* 60.5 ± 2.0*
T + ds-diabody 49.5 ± 5.5 48.7 ± 6.2 47.6 ± 3.2 48.1 ± 7.1 46.3 ± 4.6 46.0 ± 5.7 49.1 ± 4.3 49.7 ± 5.1 50.4 ± 7.2 50.7 ± 2.7 48.6 ± 2.3* 48.6 ± 2.6*
T + Ara-C 77.0 ± 8.1 77.8 ± 7.4 67.3 ± 3.3 68.0 ± 4.6 70.1 ± 5.6 69.9 ± 6.9 72.0 ± 6.8 70.8 ± 3.8 75.1 ± 5.3 75.5 ± 5.5 72.3 ± 5.0 72.4 ± 2.5
T + Ara-C + diabody 21.5 ± 3.2 20.8 ± 2.8 15.8 ± 3.1 15.0 ± 3.3 14.3 ± 2.7 13.9 ± 3.7 19.7 ± 2.1 19.1 ± 0.9 17.8 ± 1.1 17.9 ± 2.7 17.8 ± 3.5** 17.3 ± 3.4**
T + Ara-C + ds-diabody 1.3 ± 0.5 1.2 ± 0.4 0.8 ± 0.2 0.7 ± 0.1 0.7 ± 0.2 0.5 ± 0.1 2.5 ± 0.3 2.4 ± 0.4 2.0 ± 1.2 2.1 ± 0.5 1.5 ± 0.8** 1.4 ± 0.9**
  1. *p < 0.05; **p < 0.01